Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).
Scott J. Antonia, MD, PhD
Advertisement
Articles by Scott J. Antonia, MD, PhD
Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses the promise of immunotherapy in patients with non–small cell lung cancer.
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
ByShailaja Raj MD,Gregory Springett MD PhD,Daniel Indelicato MD,Marilyn Bui, MD, PhD,Anthony Conley MD,Sergio Lavilla-Alonso PhD,Xiuhua Zhao MS,Dungsa Chen PhD,Randy Haysek MD,Ricardo Gonzalez MD,Douglas Letson MD,Steven Eric Finkelstein MD PhD,Alberto Chiappori MD,Dimitry Gabrilovitch MD PhD,Scott J. Antonia, MD, PhD
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.
Advertisement
Latest Updated Articles
Dr. Antonia on Emerging Immunotherapies in Lung CancerDecember 1st 2016
Dr. Antonia on the Promise of Immunotherapy in NSCLCMay 28th 2019
Advertisement
Advertisement
Trending on OncLive
1
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
2
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5